General Toxicity Notes
Myelosuppressive and may aggravate uremic predisposition to hemorrhage and infection.
Half-Life (Normalesrd) Hours
4-6/No data
Plasma Protein Binding %
No data
Volume Of Distribution L/Kg
No data
Dose For Normal Renal Function
150 mg q8h
Adjustment For Renal Failure Method
D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [D]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
100% [D]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
100% [D]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: None, [D]
Supplement For Dialysis [Recommendation Level]: Pd
PD: None, [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: No data
References
Brogden RN, Clissold SP. Flutamide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in advanced prostatic cancer. Drugs. 1989; 38: 185-203. [PMID: 2670515] / Goldspiel BR, Kohler DR. Flutamide: an antiandrogen for advanced prostate cancer. DICP. 1990; 24: 616-23. [PMID: 2193461]
Toxicity Notes
Antiandrogenic. Gynecomastia.